AstraZeneca reported new Phase III data for Tagrisso in resected EGFR-mutated non-small cell lung cancer and for Enhertu in previously untreated advanced HER2-mutant disease, with results presented at the 2026 World Conference on Lung Cancer in Seoul.
Updated exploratory results from the ADAURA trial showed that Tagrisso, or osimertinib, reduced the risk of death by 47% versus placebo in patients with Stage II-IIIA EGFR-mutated non-small cell lung cancer after complete tumor resection. At eight years, 74% of Tagrisso-treated patients in that primary population were estimated to be alive, compared with 58% of placebo recipients.
In the broader Stage IB-IIIA trial population, Tagrisso reduced the risk of death by 48%. Estimated eight-year overall survival was 79% with Tagrisso and 64% with placebo.
ADAURA enrolled 682 patients, who received once-daily Tagrisso 80 mg or placebo for up to three years following surgery, with adjuvant chemotherapy permitted. AstraZeneca said final safety findings were consistent with the medicine’s established profile.
Separately, the companies reported that Enhertu, or trastuzumab deruxtecan, improved progression-free survival against pembrolizumab plus platinum-pemetrexed chemotherapy in the Phase III DESTINY-Lung04 trial. The study evaluated first-line treatment of patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer carrying HER2 exon 19 or exon 20 mutations.
Median progression-free survival was 14.3 months with Enhertu, compared with 8.3 months for pembrolizumab plus chemotherapy. Enhertu reduced the risk of disease progression or death by 37%, with a hazard ratio of 0.63.
The objective response rate was 70% for Enhertu and 44.5% for the comparator regimen. Median response duration was 13.4 months and 9.7 months, respectively.
At the June 9 data cutoff, overall-survival data were not mature enough for formal testing. The median overall survival was 29.3 months with Enhertu and 33.1 months with the comparator regimen.
Grade 3 or higher treatment-related adverse events occurred in 34.1% of Enhertu recipients and 33.6% of comparator recipients. Interstitial lung disease or pneumonitis occurred in 20.8% of Enhertu-treated patients, including four Grade 5 events.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!